Oral non-typable Haemophilus influenzae enhances physiological mechanism of airways protection.
Oral immunotherapy with inactivated non-typeable Haemophilus influenzae (NTHi) prevents exacerbations of chronic obstructive pulmonary disease, but the mechanism is unclear. The aim of this study was to determine the mechanism of protection. This was a placebo versus active prospective study over 3 months in 64 smokers. The active treatment was three courses of oral NTHi given at monthly intervals, followed by measurement of bacteriological and immunological parameters. The results can be summarized: (i) NTHi-specific T cells increased in the placebo treatment group over time (P<0.05); (ii) the T cell response in the oral NTHi group started earlier than that in the placebo group (P<0.05); and (iii) serum NTHi-specific immunoglobulin (Ig)G had significantly greater variation in the placebo group (P<0.0001). The increase in antibody in placebos over time correlated with exposure to live H. influenzae (P<0.05) determined from culture of gargles; (iv) reduction in saliva lysozyme over time (P<0.05) was detected only in the oral NTHi treatment group. These data are consistent with T cell priming of gut lymphoid tissue by aspiration of bronchus content into the gut, with oral immunotherapy augmenting this process leading to enhanced bronchus protection. The evidence for protection was a stable IgG antibody level through the study in the oral NTHi treatment group, contrasting with an increase in antibody correlating with exposure of the airways to H. influenzae in the placebo group. Saliva lysozyme was a useful biomarker of mucosal inflammation, falling after oral NTHi consistent with a reduction in the level of intralumenal inflammation.
Clancy
R L
RL
School of Biomedical Sciences, Faculty of Health, University of Newcastle, Immunology, Hunter Area Pathology Service, HNEHS, John Hunter Hospital, Newcastle, NSW, Australia. robert.clancy@newcastle.edu.au
Dunkley
M L
ML
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D001991:Bronchitis / Q000276:immunology / Q000517:prevention & control*; D002352:Carrier Proteins / Q000032:analysis; D018450:Disease Progression; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006193:Haemophilus influenzae / Q000145:classification / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007074:Immunoglobulin G / Q000097:blood*; D007371:Interferon-gamma / Q000032:analysis; D007781:Lactoferrin; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000032:analysis; D009569:Nitric Oxide / Q000032:analysis; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000503:physiopathology / Q000628:therapy*; D012463:Saliva / Q000201:enzymology / Q000276:immunology; D012907:Smoking / Q000009:adverse effects; D013183:Sputum / Q000276:immunology / Q000382:microbiology; D013601:T-Lymphocytes / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D055815:Young Adult
D000907:Antibodies, Bacterial; D002352:Carrier Proteins; D018073:Haemophilus Vaccines; D007074:Immunoglobulin G; C490098:LTF protein, human; D015164:Vaccines, Inactivated; D009569:Nitric Oxide; D007371:Interferon-gamma; D009113:Muramidase; D007781:Lactoferrin
Thorax. 2006 Mar;61(3):250-8
16517585
Aust N Z J Med. 1990 Feb;20(1):35-8
2322199
Chest. 2000 May;117(5 Suppl 1):286S-91S
10843957
Am J Respir Crit Care Med. 2001 Dec 1;164(11):2114-9
11739144
Chest. 2006 Feb;129(2):223-224
16478834
Nat Med. 2007 May;13(5):567-9
17450149
Am Rev Respir Dis. 1989 Aug;140(2):311-6
2788377
Immunology. 1991 Sep;74(1):68-73
1937575
Immunology. 1988 Mar;63(3):499-506
2832315
Int J Immunopharmacol. 1987;9(3):283-8
3301699
Immunol Today. 1995 May;16(5):231-6
7779253
Lancet. 2007 Sep 1;370(9589):786-96
17765528
J Infect Dis. 1992 Jun;165 Suppl 1:S194-5
1588162
Sci Transl Med. 2009 Oct 28;1(4):4ra10
20368170
Immunology. 1994 Nov;83(3):362-9
7835960
Am J Respir Crit Care Med. 2009 Mar 1;179(5):375-82
19096002
Pulm Pharmacol Ther. 2006;19(3):189-99
16019244
Infect Immun. 1993 Feb;61(2):671-9
8380797
Med J Aust. 1990 Apr 16;152(8):413-6
2184330
Clin Exp Immunol. 1995 Nov;102(2):406-16
7586699
Mucosal Immunol. 2009 Sep;2(5):403-11
19587639
Chest. 2010 Apr;137(4):805-11
19952063
Lancet. 1985 Dec 21-28;2(8469-70):1395-7
2867396
Immunol Cell Biol. 1995 Oct;73(5):414-7
8595918
Curr Opin Pulm Med. 2006 Mar;12(2):118-24
16456381
Aust N Z J Med. 1991 Aug;21(4):427-32
1953532
J Exp Med. 1971 Jul 1;134(1):224-41
4934148
Proc Am Thorac Soc. 2005;2(5):417-21
16322592
Am Rev Respir Dis. 1991 Aug;144(2):324-30
1859055